Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy

Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy

ABSTRACT Background Programmed cell death protein‐1 (PD1) antibodies are currently the standard treatment for resected high‐risk melanoma, yet recurrence rate remains high. Objectives This real‐life observational study aimed to describe the outcomes of patients with resected high‐risk melanoma follo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Liza Benzoni, Anaïs Eberhardt, Sarah Milley, Safa Idoudi, Camille Trefcon, Nicolas Romain‐Scelle, Luc Thomas, Stéphane Dalle
Format:	Article
Language:	English
Published:	Wiley 2025-03-01
Series:	Cancer Medicine
Subjects:	adjuvant anti‐PD1 therapy high‐risk melanoma
Online Access:	https://doi.org/10.1002/cam4.70432
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma
by: Chloé Wirbel, et al.
Published: (2025-03-01)

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
by: Michael Weichenthal, et al.
Published: (2024-12-01)

An update on adjuvant systemic therapies in melanoma
by: Evangeline Samuel, et al.
Published: (2019-11-01)

Current treatment strategy for resectable scalp and neck melanoma
by: A. P. Polyakov, et al.
Published: (2021-08-01)

Real‐world experience of adjuvant immunotherapy for stages III–IV melanoma: A monocentric observational study
by: Manon Blaise, et al.
Published: (2025-06-01)

Elevated lactate dehydrogenase in adjuvant BRAF and MEK inhibitor therapy does not have diagnostic significance in detecting melanoma recurrence
by: Łukasz Galus, et al.
Published: (2025-03-01)

Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
by: Toni Maria Janke, et al.
Published: (2024-12-01)

Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells
by: Rong Huang, et al.
Published: (2025-05-01)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
by: Wolfram Samlowski, et al.
Published: (2023-02-01)

Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma
by: Yaru Gao, et al.
Published: (2025-03-01)

Comparison of Adjuvant and Salvage Therapy with Immune Checkpoint Inhibitors in Head and Neck Mucosal Melanoma Treated with Proton Beam Therapy: A Retrospective Cohort Study
by: Ken Horisaki, et al.
Published: (2025-07-01)

Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?
by: Alexander C.J. van Akkooi, et al.
Published: (2024-12-01)

The established of a machine learning model for predicting the efficacy of adjuvant interferon alpha1b in patients with advanced melanoma
by: Linhan Jiang, et al.
Published: (2024-11-01)

USP5-Mediated PD-L1 deubiquitination regulates immunotherapy efficacy in melanoma
by: Jiaheng Xie, et al.
Published: (2025-07-01)

Multimodal therapy with surgery and adjuvant nivolumab for late-onset multiple liver metastases of choroidal malignant melanoma: a case report
by: Ryuta Muraki, et al.
Published: (2020-07-01)

Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study
by: Charlie Yue Wang, et al.
Published: (2024-12-01)

Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy
by: Natalia Szóstak, et al.
Published: (2025-02-01)

Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment
by: Eleonora Sosa Cuevas, et al.
Published: (2024-12-01)

Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study
by: Nargiz Majidova, et al.
Published: (2025-01-01)

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma
by: Zhang J, et al.
Published: (2025-05-01)

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation
by: Julia Forschner, et al.
Published: (2025-08-01)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01)

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma
by: Teitur Sævarsson, et al.
Published: (2024-12-01)

Variation in Immune and Inflammatory Blood Markers in Advanced Melanoma Patients Treated with PD-1 Inhibitors: A Preliminary Exploratory Study
by: Lucica Madalina Bolovan, et al.
Published: (2025-06-01)

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma
by: Marek Pasek, et al.
Published: (2025-01-01)

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
by: Charlée Nardin, et al.
Published: (2025-06-01)

NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
by: Jean-Matthieu L'Orphelin, et al.
Published: (2024-11-01)

Research progress of immune checkpoint inhibitors in the treatment of acral melanoma
by: QIAN Jiajia, RUAN Cong, LIU Jiyong, XU Rui
Published: (2025-07-01)

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma
by: Luigi Liguori, et al.
Published: (2025-09-01)

Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols
by: Mariateresa Camerino, et al.
Published: (2025-12-01)

Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment
by: Mohammad Saleem, et al.
Published: (2025-04-01)

Freund’s adjuvant is a classic of vaccine adjuvants and the basis of experimental immunology
by: F.V. Hladkykh
Published: (2024-11-01)

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model
by: Muhammad Zaeem Noman, et al.
Published: (2025-12-01)

Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
by: Joseph C. Broderick, et al.
Published: (2025-06-01)

Anti-PD-1 antibody enhances homeostatic proliferation–induced antitumor immunity during lymphopenia recovery
by: Zike Yang, et al.
Published: (2025-05-01)

An in vivo avian model of human melanoma to perform rapid and robust preclinical studies
by: Loraine Jarrosson, et al.
Published: (2023-01-01)

Laparoscopic distal pancreatectomy for metastatic melanoma originating from the choroidal membrane: a case report
by: Shigeaki Baba, et al.
Published: (2021-12-01)

Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis
by: L. Leung, et al.
Published: (2025-03-01)

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)